

1 **Running title:** High Seroprevalence to *Aedes*-borne arboviruses in Ethiopia

2 **Keywords:** dengue, Zika, chikungunya, *Aedes aegypti*, Ethiopia, arbovirus, seroprevalence

3 **Title:** High Seroprevalence to *Aedes*-borne arboviruses in Ethiopia: a Cross-sectional Survey in 2024

4 **Authors:** *^{1,2}Daniel M. Parker; ³Werissaw Haileselassie; ⁴Temesgen Sisay Hailemariam; ⁵Arsema
5 Workenh; ³Salle Workineh; ¹Xiaoming Wang; ¹Ming-Chieh Lee; ^{1,2}Guiyun Yan

6 **Affiliations:**

7 1. Department of Population Health and Disease Prevention; University of California, Irvine; U.S.A

8 2. Department of Epidemiology & Biostatistics; University of California, Irvine; U.S.A

9 3. School of Public Health, College of Health Sciences; Addis Ababa University; Addis Ababa,
10 Ethiopia.

11 4. Medical Diagnostic Laboratory, Tikur Anbessa Specialized Hospital; College of Health
12 Sciences, Addis Ababa University; Addis Ababa Ethiopia

13 5. Dil chora General Hospital, Dire Dawa Health Bureau, Dire Dawa City, Ethiopia

14 **Author email addresses:**

15 DMP: dparker1@hs.uci.edu ; ORCID: <https://orcid.org/0000-0002-5352-7338>

16 WH: werissawhaileselassie@yahoo.com

17 TSH: temesegen.sisay@aau.edu.et

18 AW: Arsea2004@hotmail.com

19 SW: saleabera@yahoo.com

20 XW: xiaomiw1@uci.edu

21 ML: mingchil@uci.edu

22 GY: guiyuny@hs.uci.edu

23 *corresponding author: Daniel M. Parker; dparker1@hs.uci.edu ; ORCID: <https://orcid.org/0000-0002-5352-7338>
24 [5352-7338](https://orcid.org/0000-0002-5352-7338)

25 **ABSTRACT**

26

27 *Aedes*-borne diseases infect millions of people each year. In the last decade several arbovirus outbreaks
28 have been reported in Ethiopia. Arbovirus diagnosis and surveillance is lacking and the true burden is
29 unknown. In this study we conducted a seroprevalence survey using a commercially available test kit
30 that that tests for immunological responses to IgM and IgG for dengue (DENV), Zika (ZIKV), and
31 chikungunya (CHIKV) viruses in Dire Dawa city, eastern Ethiopia. We found a high IgG
32 seroprevalence for DENV (76%), CHIKV (44%), and ZIKV (38%), and <20% IgM seropositivity
33 across all viruses. As a comparison, we conducted serosurveillance in Addis Ababa, the national capital
34 with no reported history of arbovirus outbreaks. The highest seropositivity we found was to IgM for
35 DENV at approximately 3%. Our results suggest both past and recent widespread exposure to these
36 arboviruses, underscoring the need for improved surveillance and public health interventions in
37 Ethiopia.

38

39

40

41

42

43

44

45

46

47

48

49 BACKGROUND

50 *Aedes* borne diseases contribute significantly to the global burden of disease, and are especially
51 prevalent in tropical and subtropical settings. *Ae. aegypti*, and to a lesser extent *Ae. albopictus*, are the
52 major vectors of disease and three viruses of primary concern are are dengue virus (DENV, from genus
53 *Orthoflavivirus*), Zika (ZIKV, from genus *Orthoflavivirus*), chikungunya (CHIKV, from genus
54 *Alphavirus*).

55 DENV, CHIKV, and ZIKV viruses each represent significant public health challenges with
56 distinct impacts and distributions. DENV, endemic in tropical and subtropical regions, is responsible
57 for an estimated 400 million infections annually, with severe cases leading to dengue hemorrhagic
58 fever and dengue shock syndrome¹. CHIKV was first detected in Tanzania in 1952 and in recent years
59 has caused epidemics in Africa, Asia, Europe, and the Americas^{2,3}. The disease is characterized by
60 debilitating joint pain and arthritis that can last weeks to months, with significant economic
61 implications on top of health impacts⁴. ZIKV was first detected in Uganda in 1947 and in the last
62 decades there have been epidemics in Africa, Asia, the Americas, and the Pacific⁵. While most ZIKV
63 infections are mild, the disease has been associated with congenital abnormalities (e.g. microcephaly)
64 when transmitted from mother to fetus⁶⁻⁸. Collectively, these mosquito-borne viruses cause substantial
65 morbidity, impact quality of life, and strain healthcare systems globally.

66 While these viruses cause considerable disease globally, infections are presumptively diagnosed
67 in much of the world, based on symptoms and without laboratory confirmation of the cause of disease.
68 Dengue and chikungunya infections result in similar symptoms and may be confused in some settings
69 in the absence of laboratory confirmation. Zika viruses are often asymptomatic. All three may be
70 drastically under-diagnosed in some settings and surveillance is lacking in much of the African
71 continent so that the true burden of these diseases is unknown.

72 Seroprevalence surveys offer the possibility to evaluate both the long- and short-term
73 epidemiology of these diseases. Antibodies to IgM typically emerge shortly after infection (normally
74 within days for each virus) and can persist for months. Antibodies to IgG typically emerge weeks after
75 infection and can persist for years (in the case of dengue, may be lifelong). Seroprevalence estimates
76 from IgM are therefore normally indicative of recent epidemiology of these diseases whereas
77 seroprevalence estimates of IgG are indicative of long-term dynamics. In some high transmission
78 settings, most of the population will be seropositive before reaching adulthood^{9,10}. Cross-reactivity can
79 complicate seroprevalence surveys that attempt to distinguish exposure to these three viruses¹¹.

80 Several dengue fever outbreaks have been documented in Ethiopia since 2013, with recurrent
81 outbreaks occurring in the Eastern part of the nation¹²⁻¹⁵. Chikungunya outbreaks have also been
82 reported more recently in the Eastern part of the nation^{16,17}, and seropositivity among symptomatic
83 individuals has been reported from the Northwest¹⁸ and more recently in the Northeast part of the
84 nation in patients with suspected malaria infections¹⁹. Dire Dawa, a major city in the Eastern part of
85 Ethiopia has been repeatedly impacted by dengue infections and more recently by a major chikungunya
86 outbreak that infected over 40,000 individuals¹⁶. Entomological surveys have confirmed the presence of
87 *Ae. aegypti* in this city as well²⁰. Research on Zika infections in this setting is scarce²¹. Surveillance is
88 lacking for all three viruses.

89 The primary objective of this research were to assess the seropositivity to DENGV, CHIKV, and
90 ZIKV in Dire Dawa, Ethiopia. Since age patterns in seropositivity can reflect both recent and historical
91 transmission intensity, our goal was also to examine potential associations between age and
92 seropositivity. We conducted secondary analyses of cross-reactivity.

93 **DATA AND METHODS**

94 **Study location**

95 Dire Dawa is a major trade city in Eastern Ethiopia. The city has a hot, arid climate with a hot
96 season from February through June and a two rainy seasons: a major one from July through September
97 and a minor rainy season In March – May. Temperatures normally range from 58F to 91F (14.4C to
98 32.7C). The wettest month is normally August, with a typical month experiencing a 5 inches (12.7cm)
99 of cumulative precipitation. The estimated population of the city in 2024 is 485,558 and the city is at
100 approximately 1,276 meters elevation.

101 We conducted a seroprevalence survey in Dire Dawa in March 2024. A total of 340 individuals
102 were recruited for the survey in Dire Dawa. Individuals were selected using a household registry and a
103 table of random numbers, with households being the unit of sampling. In a selected household, all
104 individuals were invited to participate in the survey regardless of age. We specifically targeted kebeles
105 (administrative units) with known dengue outbreaks in previous years for this survey.

106 For comparison, we conducted a secondary seroprevalence survey on the outskirts of Addis
107 Ababa using the same approach (selecting individuals by household). Addis Ababa is the capital and
108 largest city in Ethiopia, with an estimated population in 2024 of 5,703,628. In contrast to Dire Dawa,
109 Addis Ababa has a mild and temperate climate, rarely experiencing temperatures above 80 F (26.7C)
110 and typically ranging from 48F to 75F (8.9C to 23.9C). The rainy season follows the same general
111 pattern as Dire Dawa, but with August typically experiencing 8 inches (20.3cm) of cumulative
112 precipitation. Addis Ababa is at an elevation of approximately 2,355 meters.

113 For this secondary survey we recruited a total of 180 individuals to the seroprevalence survey.
114 We hypothesized that exposure to *Ae. aegypti* and associated viruses would be lower in Addis Ababa
115 than in Dire Dawa and wanted to conduct this secondary survey to compare overall seroprevalence
116 results to Dire Dawa, in part because we lacked a diagnostic control. We targeted 2 kebeles in Addis
117 Ababa for this secondary survey.

118

119 **Seropositivity test**

120 We used the Chembio DPP[®] ZCD IgM/IgG system for the seroprevalence survey²². This system
121 is an immunochromatographic test, meant for detection and differentiation of IgG and IgM antibodies
122 to DENV, CHIKV, and ZIKV (i.e. each individual potentially testing positive for 6 different
123 outcomes). The test kit comes with a reader, which is used 10 to 15 minutes after adding buffer to the
124 test device.

125 The reader for the rapid diagnostic test also outputs a numeric value of the intensity of the
126 immunological response. The numeric value corresponds to the intensity of the colored lines on the test
127 device, which are proportional to the presence of antibodies. The reader uses photometry to measure
128 light reflectance from the lines on the test strip, with the intensity of reflected light being inversely
129 proportional to the relevant antibody responses. This quantitative measure provides an opportunity to
130 look at patterns of cross-reactivity across viruses and immunological measures.

131

132 **Questionnaire**

133 The survey team visited each household with a tablet that was loaded with basic demographic
134 questions (age and gender) and test responses, and test kits.

135

136 **Generalized Estimating Equations**

137 We used a generalized estimating equations (GEE) model to estimate the overall seroprevalence
138 to IgG and IgM for all three viruses, accounting for the household clustering design of the study by
139 specifying an exchangeable correlation structure. We used bootstrapping to obtain robust confidence
140 intervals around the seroprevalence estimates. We then used another GEE model to estimate age-
141 specific seropositivity to IgG and IgM to each of the three viruses (DENV, CHIKV, and ZIKV). To
142 model the relationship between age and seropositivity, we incorporated natural spline functions,

143 allowing us to capture potential non-linear patterns in seropositivity across age. The model estimated
144 the probability of being seropositive for each virus as a function of age, adjusted for household
145 clustering. We then used these model estimates to generate predicted probabilities of seropositivity
146 across age groups. Confidence intervals for these predictions were calculated by deriving the standard
147 errors of the linear predictor, which were then transformed to the probability scale using the logistic
148 function. These predicted probabilities, along with their 95% confidence intervals, were plotted to
149 visualize how IgG and IgM seropositivity changes with age for each virus, while accounting for
150 clustering at the household level.

151

152 **Assessment of cross-reactivity**

153 We used linear mixed models, with the quantitative immunological measures for each of the
154 viruses and for both IgG and IgM as outcome variables, and with the other IgG or IgM measures for
155 each virus as predictors, while accounting for household clustering using a random intercept for
156 household. For models that used IgM measures as the outcome we also included IgG measures as
157 covariates because we hypothesized that previous exposure to other viruses could potential impact
158 immunological reactions to a more recent infection.

159

160 **Assessment of household clustering**

161 The use of linear mixed models in our assessment of cross-reactivity also allowed us to
162 investigate household clustering in immunological responses. To quantify household clustering we used
163 the intraclass correlation coefficient (ICC). The ICC quantifies the proportion of variance attributable
164 to between-group differences (in this case, households) compared to within-group differences
165 (individuals). The mixed models were fitted with random intercepts for households, allowing us to
166 estimate the variance in responses across households. By comparing the random intercept variance to

167 the total variance (random intercept variance plus residual variance), we calculated the ICC for each
168 model. This provided insight into how much of the variation in IgG and IgM responses could be
169 attributed to clustering within households versus individual-level variability.

170

171 **Ethics review**

172 Ethics approval was obtained from the Institutional Review Board of the College of Health Sciences,
173 Addis Ababa University. Verbal and written informed consent were required from individuals before
174 participating in the study. Assent/consent for participation for those under 18 years old was granted by
175 their parent or legal guardian.

176

177

178 **RESULTS**

179 **Overall seroprevalence**

180 A total of 340 individuals were recruited for the seroprevalence survey in Dire Dawa.
181 Seropositivity to dengue virus IgG was 76% (95% Cis: 0.71 – 0.80). Chikungunya and Zika IgG
182 seropositivity were 44% (0.38 – 0.50) and 38% (0.31 – 0.44), respectively. Seropositivity to IgM
183 antibodies, typically indicating recent infections, was much lower (**Table 1**). Dengue and chikungunya
184 IgM was approximately the same (0.17 (0.13 – 0.21) versus 0.18 (0.13 – 0.22), respectively). Zika IgM
185 was much lower, at approximately 0.03 (0.02 – 0.05).

186 In comparison, few individuals from the secondary seroprevalence survey in Addis Ababa tested
187 positive (not enough for accurate seroprevalence estimates). A total of 180 individuals were recruited in
188 this survey and out of them 5 tested positive for DENV IgG, 2 for ZIKV IgG, and 1 for CHIKV IgG.
189 Six tested positive for DENV IgM, 1 tested positive for ZIKV IgM, and 1 tested positive for CHIKV
190 IgM. Again, each of the ZIKV IgG positives were also DENV IgG positive. A total of 11 individuals

191 were found seropositive (combining IgG and IgM, and for all three viruses), these individuals ranged in
192 age from 25 to 36 (mean = 30.2; median = 28), and each reported travel to other regions in Ethiopia
193 (five specifically mentioned travel to Dire Dawa).

194

195 **Age patterns in seropositivity**

196 Age patterns in predicted probability of seropositivity (**Figure 1**) largely followed the age
197 patterns of the age-specific seropositivity calculations (**Supplemental Figure 1**). By age 10, 52% of all
198 sampled individuals were seropositive to dengue IgG. By age 40, approximately 86% of all sampled
199 individuals were seropositive to dengue IgG. By age 30, over half (51%) of all individuals were
200 seropositive to chikungunya IgG. Finally, by age 20 over 37% of all individuals were seropositive to
201 Zika IgG. The potential cross-over between IgM for dengue and chikungunya was likewise evident in
202 these estimates, though the confidence bands around the estimates were sufficiently large to warrant
203 caution in interpreting this result.

204 **Potential for cross reactivity**

205 All Zika IgG positive individuals were also dengue IgG positive, suggesting a potential for
206 cross-reactivity. Indeed, both are flaviviruses (i.e. genus *Orthoflavivirus*), and so cross-reactivity would
207 not be surprising. 253 of the tested individuals were dengue IgG seropositive and 126 were Zika IgG
208 positive.

209 An analysis of the quantified immunological response to IgG antibodies for Zika and dengue
210 showed that individuals who were categorized as Zika IgG negative but dengue IgG positive had very
211 low Zika IgG responses. Those who were both Zika IgG and dengue IgG positive had much higher
212 responses than those who were dengue IgG positive but not Zika IgG positive (**Supplemental Figure**
213 **2**).

214 Individuals who were dengue IgG positive and Zika IgG positive had significantly higher
215 quantitative dengue IgG values when compared to those who were dengue IgG reactive but Zika IgG
216 non-reactive (**Supplemental Table 2C**). In general, cross reactivity was high with regard to
217 quantitative dengue IgG outcomes for those who have had a previous Zika exposure. The inverse (cross
218 reactivity where dengue virus exposure increases Zika IgG) appears minimal in comparison. We
219 therefore hypothesize that the Zika IgG positives are not solely the results of cross-reactivity with
220 dengue virus but rather indication of true previous infections with Zika virus. Furthermore, not all Zika
221 IgM positives were also dengue IgM positive.

222 We generated a Spearman's correlation matrix from all possible immunological outcomes
223 (**Figure 2**). The strongest associations were between Zika IgG and dengue IgG, chikungunya IgG and
224 chikungunya IgM, followed by Zika IgG and dengue IgM, and dengue IgG and IgM.

225 Our linear mixed models analyses (**Supplemental Tables 1 and 2**) showed that Zika IgG was a
226 strong predictor of dengue IgG values (**Supplemental Table 1**). Chikungunya IgG was also associated
227 but the association was smaller than with Zika IgG. Dengue IgG was a strong predictor of Zika IgG.
228 Chikungunya IgG was negatively associated with Zika IgG. Finally, Zika IgG was positively associated
229 with chikungunya IgG values while dengue IgG was negatively associated with chikungunya IgG.

230 Zika IgM was positively associated with dengue IgM, as was chikungunya IgM (**Supplemental**
231 **Table 2**). Likewise, dengue and chikungunya IgM values were positively associated with Zika IgM.
232 Finally, dengue and Zika IgM were both positively associated with chikungunya IgM. IgG values were
233 statistically significant predictors of each IgM outcome, but their effect sizes were small.

234

235 **Household clustering**

236 The ICC values revealed varying degrees of household clustering for the different viruses and
237 immune responses. For DENV, we observed moderate clustering in IgG responses (ICC = 10.3%) and

238 a low degree of clustering for IgM responses (ICC = 1.8%). CHIKV showed a similar pattern, with
239 clustering in IgG (ICC = 7.1%) and a stronger clustering effect in IgM responses (ICC = 14.0%). Zika,
240 on the other hand, displayed no household-level clustering for either IgG or IgM responses (ICC = 0
241 for both). These results suggest that household membership affected the variability in DENGV and
242 CHIKV responses to a moderate extent, while it had no impact on ZIKV responses.

243

244 **DISCUSSION**

245 Using a cross-sectional seroprevalence survey from Dire Dawa, Ethiopia we found and here
246 report a high seroprevalence to three arboviruses of concern: DENV, CHIKV, and ZIKV. These results
247 existed for both IgG and IgM suggesting both a history of widespread exposure to these viruses, and
248 recent exposure. The age patterns for DENV and CHIKV IgG seroprevalence in particular suggest that
249 most of the population in this setting has been exposed to these viruses by age 30 (over 50%
250 seroprevalence to CHIKV IgG and over 80% to DENGV IgG). We also found evidence of household
251 clustering with regard to DENGV and CHIKV exposure, but not ZIKV exposure.

252 While approximately 25% of all children ages 0 – 4 were seropositive to DENGV IgG, none
253 were seropositive to CHIKV IgG. In 2019 there was a major CHIKV outbreak in this setting, with over
254 40,000 individuals diagnosed with the disease¹⁶. It is therefore possible that much of the seroprevalence
255 to CHIKV IgG that we found was the result of this previous epidemic, or to the 2019 epidemic and
256 others. We did, however, find individuals in most ages (but not the youngest age group) who were
257 seropositive to CHIKV IgM, suggesting that there has potentially been some recent transmission of this
258 disease or a related alphavirus, among individuals from the study location. IgM to Chikungunya has
259 been shown to persist in some individuals over long periods of time (28 months post infection²³) but we
260 believe this is unlikely to explain the IgM seropositivity to CHIKV from our survey (now 5 years after
261 the major 2019 epidemic).

262 While dengue and chikungunya epidemics have previously been reported in Ethiopia, data on
263 exposure to Zika is scarce. One survey from Gambella (in far West Ethiopia) estimated 2.9, 15.6, and
264 27.3% seroprevalence for Yellow Fever, chikungunya, and Zika virus²⁴. Another report of Zika
265 seropositivity in Ethiopia²¹. Zika virus disease has been reported in traveler to Europe coming from
266 Kenya²⁵. Zika virus was originally discovered on the African continent, but surveillance remains low⁵.

267 One limitation of our work is the use of a single screening kit. It might have been preferable to
268 have another test (e.g. ELISA) for comparison on at least a subsample. A few other studies have used
269 the same test kit in research settings. One study suggested general low sensitivity of this test in
270 comparison to ELISA. However, specificity was high (sensitivity/specificity: Dengue 43.92/100%;
271 Zika 25.86/98.81%; CHIKV 37.78/99.35%). If the same pattern holds true in this setting it would
272 indicate that the estimated seroprevalence is an underestimate²⁶. Another study focusing on IgM alone
273 found sensitivity/specificity of the ZCD test to Zika IgM was 79.0/97.1%; dengue was 90.0/89.2%; and
274 for chikungunya it was 90.6/97.2%²⁷. We take the results of these previous studies to suggest that for
275 ZIKV and CHIKV in particular, our results may be underestimates.

276 Cross reactivity may have influenced some of our results. DENGV and ZIKV are both
277 flaviviruses, and cross-reactivity between the two is well-known but not completely understood^{11,28,29}. If
278 other alphaviruses are circulating in this setting, they could potentially lead to false-positive CHIKV
279 seropositivity. Cross-reactivity can have clinical implications, as is already well-known within DENGV
280 infections across serotypes and has been hypothesized between DENGV and ZIKV infections. While
281 DENGV infections are known to provide long-term immunity, the immunity is sero-type specific and
282 infection by another serotype can lead to more severe disease outcomes (including death) through
283 antibody dependent enhancement (ADE)³⁰⁻³². ADE may also occur across flaviviruses – with the
284 potential for previous ZIKV infection leading to severe dengue disease even in the primary infection by
285 DENGV³³. Current dengue vaccines are only provided to populations that already have previous

286 exposure to DENGV (i.e. the vaccines should only be provided to seropositive individuals) as
287 vaccinating individuals who are seronegative can increase their risk of severe disease when they are
288 infected by DENGV³⁴.

289 Cross-reactivity is further complicated by the fact that these three viruses are all vectored by the
290 same mosquito (e.g. *Ae. aegypti*), meaning that individuals who have been infected with dengue in this
291 setting are likely to also have been at risk of chikungunya (which has been confirmed in this setting)
292 and Zika virus infection, if the respective viruses are present in, or introduced to, this location. That is,
293 individuals in this setting who acquire dengue infections are likely to also be at risk of CHIKV or
294 ZIKV infections, if those viruses are present, given the shared mosquito vector that is present in this
295 setting.

296 This seroprevalence survey was meant to look for age-specific seroprevalence in kebeles in Dire
297 Dawa that are known to have previously had dengue outbreaks. While we used a clustered random
298 sampling approach (randomly selecting households within the kebeles), our results may not be
299 representative of the entire city of Dire Dawa. It would be valuable to conduct further surveys that
300 would be representative of the city, as well as in other parts of Ethiopia.

301 In summary, we found evidence of widespread exposure to DENGV, CHIKV, and ZIKV in Dire
302 Dawa, Ethiopia. This aligns with reported outbreaks of dengue fever in this setting, and of the massive
303 chikungunya fever outbreak in 2019. We also found evidence of exposure to ZIKV, which has rarely
304 been reported from this nation. Not only did we find evidence of previous exposure to ZIKV, we also
305 found evidence of recent exposure (i.e. IgM seropositivity) to all three arboviruses. While we cannot
306 rule out the potential for cross-reactivity influencing our results, they are suggestive of a large burden
307 of *Ae. aegypti*-borne diseases in a setting where this important vector of disease is known to be present.
308 Repeated infections can in some cases lead to more severe disease outcomes, for example through
309 ADE. More research into arboviral diseases and their mosquito vectors in this setting is warranted both

310 to confirm our results and to develop a better understanding of the burden of different arboviral
311 diseases, any potential age and gender associated risk factors, and all so that public health interventions
312 can be formulated to address these diseases. As the world has experienced pandemic levels of *Aedes*-
313 borne disease several times since 2019, it is increasingly important to have increased surveillance for
314 these diseases and for public health agencies to plan accordingly.

315

316

317 **ACKNOWLEDGMENTS**

318 We are thankful for the community members and community health workers in Dire Dawa and Addis
319 Ababa who participated in this research.

320

321 **FINANCIAL SUPPORT**

322 This study was partially funded through a Council on Research, Computing and Libraries (CORCL)
323 pilot grant to DMP and through NIH grants D43 TW001505 and U19 AI129326 to GY.

324

325

326

327

328

329

330

331

332

333

334 REFERENCES

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature*. 2013;496(7446):504-507. doi:10.1038/nature12060
2. Chikungunya fact sheet. Accessed August 26, 2024. <https://www.who.int/news-room/fact-sheets/detail/chikungunya>
3. Staples JE, Breiman RF, Powers AM. Chikungunya Fever: An Epidemiological Review of a Re-Emerging Infectious Disease. *Clinical Infectious Diseases*. 2009;49(6):942-948. doi:10.1086/605496
4. Mora-Salamanca AF, Porrás-Ramírez A, De la Hoz Restrepo FP. Estimating the burden of arboviral diseases in Colombia between 2013 and 2016. *International Journal of Infectious Diseases*. 2020;97:81-89. doi:10.1016/j.ijid.2020.05.051
5. Zika virus. Accessed August 26, 2024. <https://www.who.int/news-room/fact-sheets/detail/zika-virus>
6. Araújo TVB de, Ximenes RA de A, Miranda-Filho D de B, et al. Association between microcephaly, Zika virus infection, and other risk factors in Brazil: final report of a case-control study. *The Lancet Infectious Diseases*. 2018;18(3):328-336. doi:10.1016/S1473-3099(17)30727-2
7. Oliveira WK de, França GVA de, Carmo EH, Duncan BB, Kuchenbecker R de S, Schmidt MI. Infection-related microcephaly after the 2015 and 2016 Zika virus outbreaks in Brazil: a surveillance-based analysis. *The Lancet*. 2017;390(10097):861-870. doi:10.1016/S0140-6736(17)31368-5
8. Musso D, Ko AI, Baud D. Zika Virus Infection — After the Pandemic. *New England Journal of Medicine*. 2019;381(15):1444-1457. doi:10.1056/NEJMra1808246

9. Rodríguez-Barraquer I, Buathong R, Iamsirithaworn S, et al. Revisiting Rayong: Shifting Seroprofiles of Dengue in Thailand and Their Implications for Transmission and Control. *American Journal of Epidemiology*. 2014;179(3):353-360. doi:10.1093/aje/kwt256
10. Vongpunsawad S, Intharasongkroh D, Thongmee T, Poovorawan Y. Seroprevalence of antibodies to dengue and chikungunya viruses in Thailand. *PLOS ONE*. 2017;12(6):e0180560. doi:10.1371/journal.pone.0180560
11. Priyamvada L, Suthar MS, Ahmed R, Wrammert J. Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity. *The Journal of Infectious Diseases*. 2017;216(suppl_10):S906-S911. doi:10.1093/infdis/jix513
12. Shimelis T, Mulu A, Mengesha M, et al. Detection of dengue virus infection in children presenting with fever in Hawassa, southern Ethiopia. *Sci Rep*. 2023;13(1):7997. doi:10.1038/s41598-023-35143-2
13. Gutu MA, Bekele A, Seid Y, et al. Another dengue fever outbreak in Eastern Ethiopia—An emerging public health threat. *PLoS Negl Trop Dis*. 2021;15(1):e0008992. doi:10.1371/journal.pntd.0008992
14. Mesfin Z, Ali A, Abagero A, Asefa Z. Dengue Fever Outbreak Investigation in Werder Town, Dollo Zone, Somali Region, Ethiopia. *Infect Drug Resist*. 2022;15:7207-7217. doi:10.2147/IDR.S368562
15. Degife LH, Worku Y, Belay D, Bekele A, Hailemariam Z. Factors associated with dengue fever outbreak in Dire Dawa administration city, October, 2015, Ethiopia - case control study. *BMC Public Health*. 2019;19(1):650. doi:10.1186/s12889-019-7015-7

16. Geleta D, Tesfaye N, Ayigeqn H, Waldetensai A, Gemechu F, Amare H. Epidemiological Description of Chikungunya Virus Outbreak in Dire Dawa Administrative City, Eastern Ethiopia, 2019. *Int J Clin Exp Med Sci*. 2020;6(3):41-45. doi:10.11648/j.ijcems.20200603.13
17. Chikungunya disease outbreak affects 20,000 people in Ethiopia - Xinhua | English.news.cn.http://www.xinhuanet.com/english/2019-09/03/c_138362347.htm. Accessed August 26, 2024.
18. Ferede G, Tiruneh M, Abate E, et al. Evidence of chikungunya virus infection among febrile patients in northwest Ethiopia. *International Journal of Infectious Diseases*. 2021;104:183-188. doi:10.1016/j.ijid.2020.12.057
19. Zerfu B, Kassa T, Mamo G, Larrick JW, Legesse M. High seroprevalence of IgM antibodies against chikungunya among patients with acute febrile illness seeking healthcare in a malaria-endemic area in the Afar Region, Northeast Ethiopia. *SAGE Open Medicine*. 2024;12:20503121241276557. doi:10.1177/20503121241276557
20. Yared S, Gebressilasie A, Worku A, et al. Breeding habitats, bionomics and phylogenetic analysis of *Aedes aegypti* and first detection of *Culiseta longiareolata*, and *Ae. hirsutus* in Somali Region, eastern Ethiopia. *PLOS ONE*. 2024;19(1):e0296406. doi:10.1371/journal.pone.0296406
21. Mengesha Tsegaye M, Beyene B, Ayele W, et al. Sero-prevalence of yellow fever and related Flavi viruses in Ethiopia: a public health perspective. *BMC Public Health*. 2018;18(1):1011. doi:10.1186/s12889-018-5726-9
22. *Chembio DPP® ZCD IgM/IgG System*. Accessed September 18, 2024. <https://chembio.com/wp-content/uploads/2021/12/MSDS-018-DPP-ZCD-IgM-IgG-System-65-9565-0-Rev-1.pdf>

23. Costa DM do N, Coêlho MRCD, Gouveia PA da C, et al. Long-Term Persistence of Serum-Specific Anti-Chikungunya IgM Antibody - A Case Series of Brazilian Patients. *Rev Soc Bras Med Trop*. 54:e0855-2020. doi:10.1590/0037-8682-0855-2020
24. Asebe G, Michlmayr D, Mamo G, et al. Seroprevalence of Yellow fever, Chikungunya, and Zika virus at a community level in the Gambella Region, South West Ethiopia. *PLOS ONE*. 2021;16(7):e0253953. doi:10.1371/journal.pone.0253953
25. Gossner CM, Hallmaier-Wacker L, Briet O, et al. Arthropod-borne diseases among travellers arriving in Europe from Africa, 2015 to 2019. *Eurosurveillance*. 2023;28(7):2200270. doi:10.2807/1560-7917.ES.2023.28.7.2200270
26. Chakma R, Sriburin P, Sittikul P, et al. Arbovirus Seroprevalence Study in Bangphae District, Ratchaburi Province, Thailand: Comparison between ELISA and a Multiplex Rapid Diagnostic Test (Chembio DPP® ZCD IgG). *Tropical Medicine and Infectious Disease*. 2022;7(11):378. doi:10.3390/tropicalmed7110378
27. Boeras D, Diagne CT, Pelegrino JL, et al. Evaluation of Zika rapid tests as aids for clinical diagnosis and epidemic preparedness. *EClinicalMedicine*. 2022;49:101478. doi:10.1016/j.eclinm.2022.101478
28. Priyamvada L, Hudson W, Ahmed R, Wrammert J. Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology. *Emerging Microbes & Infections*. 2017;6(1):1-6. doi:10.1038/emi.2017.42
29. Wen J, Shresta S. Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine? *Current Opinion in Immunology*. 2019;59:1-8. doi:10.1016/j.coi.2019.02.001

30. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. *Arch Virol*. 2013;158(7):1445-1459. doi:10.1007/s00705-013-1645-3
31. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. *Adv Virus Res*. 2003;60:421-467. doi:10.1016/s0065-3527(03)60011-4
32. Pang T, Cardoso MJ, Guzman MG. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). *Immunology & Cell Biology*. 2007;85(1):43-45. doi:10.1038/sj.icb.7100008
33. Bonheur AN, Thomas S, Soshnick SH, et al. A fatal case report of antibody-dependent enhancement of dengue virus type 1 following remote Zika virus infection. *BMC Infectious Diseases*. 2021;21(1):749. doi:10.1186/s12879-021-06482-0
34. Robinson ML, Durbin AP. Dengue vaccines: implications for dengue control. *Curr Opin Infect Dis*. 2017;30(5):449-454. doi:10.1097/QCO.0000000000000394

335

336

337

338

339

340

341

342 **FIGURES:**

343

344 **Figure 1:** Age specific probability of IgG and IgM seropositivity from the GEE models

345

346 **Figure 2:** Spearman correlation matrix for correlations between IgG and IgM for each arbovirus

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366 **TABLES**

367 **Table 1:** Seropositivity estimates and confidence intervals, from GEE models using an exchangeable
368 correlation structure to account for potential clustering in households.

369

		Serporevalence	
	Disease	Estimate	95% Cis
IgG	Dengue	0.76	(0.71 – 0.80)
	Chikungunya	0.44	(0.38 – 0.50)
	Zika	0.38	(0.31 – 0.44)
IgM	Dengue	0.17	(0.13 – 0.21)
	Chikungunya	0.18	(0.13 – 0.22)
	Zika	0.03	(0.02 – 0.05)

370

371

372

373

374

375

376


377

378


379

380

Predicted Probability of IgG Seropositivity by Age



Predicted Probability of IgM Seropositivity by Age



Spearman Correlation Matrix of IgG and IgM Values

